公开(公告)号：US11759465B2

公开(公告)日：2023-09-19

申请号：US16892206

申请日：2020-06-03

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： David Kass ,  Toru Hashimoto ,  Lawrence P. Wennogle ,  Joseph Hendrick ,  Robert Davis

IPC: A61K31/519 ,  A61P9/04 ,  A61K31/197 ,  A61K31/216 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/7056 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K31/197 ,  A61K31/216 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/7056 ,  A61K45/06 ,  A61P9/04

Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

公开(公告)号：US09849132B2

公开(公告)日：2017-12-26

申请号：US15110640

申请日：2015-01-08

Applicant: Intra-Cellular Therapies, Inc.

Inventor： Joseph Hendrick ,  Jennifer O'Brien ,  Gretchen Snyder ,  Peng Li ,  Lawrence P. Wennogle

IPC: A61K31/519 ,  A61K31/53 ,  A61K45/06 ,  C07D487/04 ,  C07D487/14 ,  A61K9/00

CPC classification number: A61K31/519 ,  A61K9/0048 ,  A61K31/53 ,  A61K45/06 ,  C07D487/04 ,  C07D487/14 ,  A61K2300/00

Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.

公开(公告)号：US11839614B2

公开(公告)日：2023-12-12

申请号：US16966818

申请日：2019-01-31

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： David Kass ,  Toru Hashimoto ,  Lawrence Wennogle ,  Joseph Hendrick ,  Robert Davis

IPC: A61K31/519 ,  A61P9/04 ,  A61K31/41 ,  A61K31/7056 ,  A61K9/00 ,  A61K45/06 ,  A61K31/197 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/04

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K31/04 ,  A61K31/197 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/7056 ,  A61K45/06 ,  A61P9/04

Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

公开(公告)号：US10300064B2

公开(公告)日：2019-05-28

申请号：US15533527

申请日：2015-12-07

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li ,  Hailin Zheng ,  Gretchen Snyder ,  Lawrence P. Wennogle ,  Joseph Hendrick

IPC: C07D487/04 ,  C07D403/14 ,  C07D401/14 ,  A61K31/519 ,  A61P25/28 ,  A61P9/12 ,  C07D231/06 ,  C07D231/54

Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.

公开(公告)号：US11291666B2

公开(公告)日：2022-04-05

申请号：US16332750

申请日：2017-09-12

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Gretchen Snyder ,  Lawrence P. Wennogle ,  Jennifer O'Brien ,  Joseph Hendrick

IPC: A61K31/517 ,  A61K31/519 ,  A61P27/02 ,  A61P25/28 ,  A61P37/06 ,  A61K31/4015 ,  A61K45/06

Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.

公开(公告)号：US10543194B2

公开(公告)日：2020-01-28

申请号：US16125373

申请日：2018-09-07

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li ,  Hailin Zheng ,  Gretchen Snyder ,  Lawrence P. Wennogle ,  Joseph Hendrick

IPC: A61K31/4162 ,  C07D471/14 ,  C07D209/58 ,  C07D403/14

Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.

公开(公告)号：US10105349B2

公开(公告)日：2018-10-23

申请号：US15533525

申请日：2015-12-07

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li ,  Hailin Zheng ,  Gretchen Snyder ,  Lawrence P. Wennogle ,  Joseph Hendrick

IPC: A61K31/4162 ,  C07D471/14 ,  C07D403/14 ,  C07D209/58

Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.